Small PrEP RCT showing that PrEP with HCQ is safe at the dosage used. No deaths, hospitalizations, or serious adverse events. With only one case (in the placebo arm), efficacy was not evaluated.
The abstract appears to have a typo and does not match the results section. We believe the results section is correct with one case in the control arm - the 0.8% matches the percentage for the control arm (there is no possible number of cases for the combined arms that matches 0.8%). Note that table 2 refers to risk factors, not outcomes.
Grau-Pujol et al., 9/21/2020, Randomized Controlled Trial, Spain, Europe, preprint, 22 authors.
risk of COVID-19 case, 67.9% lower, RR 0.32, p = 0.47, treatment 0 of 142 (0.0%), control 1 of 127 (0.8%).
Effect extraction follows pre-specified rules prioritizing more serious
outcomes. For an individual study the most serious outcome may have a smaller
number of events and lower statistical signficance, however this provides the
strongest evidence for the most serious outcomes when combining the results of